317 related articles for article (PubMed ID: 10728703)
1. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas.
Frederick L; Wang XY; Eley G; James CD
Cancer Res; 2000 Mar; 60(5):1383-7. PubMed ID: 10728703
[TBL] [Abstract][Full Text] [Related]
2. The Role of Genetic Analysis in Distinguishing Multifocal and Multicentric Glioblastomas: An Illustrative Case.
Karatsu K; Tamura R; Yo M; Nogawa H; Hino U; Kitamura Y; Ueda R; Toda M
Case Rep Oncol; 2024; 17(1):113-121. PubMed ID: 38260034
[TBL] [Abstract][Full Text] [Related]
3. Genetics of Glioblastoma in Moroccan population: Review of literature.
Idrissi HHE; Boujmia OKA; Nadifi S; Dehbi H
IBRO Rep; 2018 Dec; 5():133-136. PubMed ID: 30569026
[TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain.
Lee JC; Vivanco I; Beroukhim R; Huang JH; Feng WL; DeBiasi RM; Yoshimoto K; King JC; Nghiemphu P; Yuza Y; Xu Q; Greulich H; Thomas RK; Paez JG; Peck TC; Linhart DJ; Glatt KA; Getz G; Onofrio R; Ziaugra L; Levine RL; Gabriel S; Kawaguchi T; O'Neill K; Khan H; Liau LM; Nelson SF; Rao PN; Mischel P; Pieper RO; Cloughesy T; Leahy DJ; Sellers WR; Sawyers CL; Meyerson M; Mellinghoff IK
PLoS Med; 2006 Dec; 3(12):e485. PubMed ID: 17177598
[TBL] [Abstract][Full Text] [Related]
5. The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered.
Gan HK; Cvrljevic AN; Johns TG
FEBS J; 2013 Nov; 280(21):5350-70. PubMed ID: 23777544
[TBL] [Abstract][Full Text] [Related]
6. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
Lynch TJ; Bell DW; Sordella R; Gurubhagavatula S; Okimoto RA; Brannigan BW; Harris PL; Haserlat SM; Supko JG; Haluska FG; Louis DN; Christiani DC; Settleman J; Haber DA
N Engl J Med; 2004 May; 350(21):2129-39. PubMed ID: 15118073
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance.
Aldape KD; Ballman K; Furth A; Buckner JC; Giannini C; Burger PC; Scheithauer BW; Jenkins RB; James CD
J Neuropathol Exp Neurol; 2004 Jul; 63(7):700-7. PubMed ID: 15290895
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme.
Shinojima N; Tada K; Shiraishi S; Kamiryo T; Kochi M; Nakamura H; Makino K; Saya H; Hirano H; Kuratsu J; Oka K; Ishimaru Y; Ushio Y
Cancer Res; 2003 Oct; 63(20):6962-70. PubMed ID: 14583498
[TBL] [Abstract][Full Text] [Related]
9. The somatic genomic landscape of glioblastoma.
Brennan CW; Verhaak RG; McKenna A; Campos B; Noushmehr H; Salama SR; Zheng S; Chakravarty D; Sanborn JZ; Berman SH; Beroukhim R; Bernard B; Wu CJ; Genovese G; Shmulevich I; Barnholtz-Sloan J; Zou L; Vegesna R; Shukla SA; Ciriello G; Yung WK; Zhang W; Sougnez C; Mikkelsen T; Aldape K; Bigner DD; Van Meir EG; Prados M; Sloan A; Black KL; Eschbacher J; Finocchiaro G; Friedman W; Andrews DW; Guha A; Iacocca M; O'Neill BP; Foltz G; Myers J; Weisenberger DJ; Penny R; Kucherlapati R; Perou CM; Hayes DN; Gibbs R; Marra M; Mills GB; Lander E; Spellman P; Wilson R; Sander C; Weinstein J; Meyerson M; Gabriel S; Laird PW; Haussler D; Getz G; Chin L;
Cell; 2013 Oct; 155(2):462-77. PubMed ID: 24120142
[TBL] [Abstract][Full Text] [Related]
10. Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors.
Vivanco I; Robins HI; Rohle D; Campos C; Grommes C; Nghiemphu PL; Kubek S; Oldrini B; Chheda MG; Yannuzzi N; Tao H; Zhu S; Iwanami A; Kuga D; Dang J; Pedraza A; Brennan CW; Heguy A; Liau LM; Lieberman F; Yung WK; Gilbert MR; Reardon DA; Drappatz J; Wen PY; Lamborn KR; Chang SM; Prados MD; Fine HA; Horvath S; Wu N; Lassman AB; DeAngelis LM; Yong WH; Kuhn JG; Mischel PS; Mehta MP; Cloughesy TF; Mellinghoff IK
Cancer Discov; 2012 May; 2(5):458-71. PubMed ID: 22588883
[TBL] [Abstract][Full Text] [Related]
11. Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies.
Cho J; Pastorino S; Zeng Q; Xu X; Johnson W; Vandenberg S; Verhaak R; Cherniack AD; Watanabe H; Dutt A; Kwon J; Chao YS; Onofrio RC; Chiang D; Yuza Y; Kesari S; Meyerson M
Cancer Res; 2011 Dec; 71(24):7587-96. PubMed ID: 22001862
[TBL] [Abstract][Full Text] [Related]
12. Molecular analysis of the EGFR gene in astrocytic gliomas: mRNA expression, quantitative-PCR analysis of non-homogeneous gene amplification and DNA sequence alterations.
Arjona D; Bello MJ; Alonso ME; Aminoso C; Isla A; De Campos JM; Sarasa JL; Gutierrez M; Villalobo A; Rey JA
Neuropathol Appl Neurobiol; 2005 Aug; 31(4):384-94. PubMed ID: 16008822
[TBL] [Abstract][Full Text] [Related]
13. The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling.
Huang HS; Nagane M; Klingbeil CK; Lin H; Nishikawa R; Ji XD; Huang CM; Gill GN; Wiley HS; Cavenee WK
J Biol Chem; 1997 Jan; 272(5):2927-35. PubMed ID: 9006938
[TBL] [Abstract][Full Text] [Related]
14. EGFR-induced and PKCε monoubiquitylation-dependent NF-κB activation upregulates PKM2 expression and promotes tumorigenesis.
Yang W; Xia Y; Cao Y; Zheng Y; Bu W; Zhang L; You MJ; Koh MY; Cote G; Aldape K; Li Y; Verma IM; Chiao PJ; Lu Z
Mol Cell; 2012 Dec; 48(5):771-84. PubMed ID: 23123196
[TBL] [Abstract][Full Text] [Related]
15. Emerging insights into the molecular and cellular basis of glioblastoma.
Dunn GP; Rinne ML; Wykosky J; Genovese G; Quayle SN; Dunn IF; Agarwalla PK; Chheda MG; Campos B; Wang A; Brennan C; Ligon KL; Furnari F; Cavenee WK; Depinho RA; Chin L; Hahn WC
Genes Dev; 2012 Apr; 26(8):756-84. PubMed ID: 22508724
[TBL] [Abstract][Full Text] [Related]
16. Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance.
Taylor TE; Furnari FB; Cavenee WK
Curr Cancer Drug Targets; 2012 Mar; 12(3):197-209. PubMed ID: 22268382
[TBL] [Abstract][Full Text] [Related]
17. Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment.
Jura N; Endres NF; Engel K; Deindl S; Das R; Lamers MH; Wemmer DE; Zhang X; Kuriyan J
Cell; 2009 Jun; 137(7):1293-307. PubMed ID: 19563760
[TBL] [Abstract][Full Text] [Related]
18. Malignant astrocytic glioma: genetics, biology, and paths to treatment.
Furnari FB; Fenton T; Bachoo RM; Mukasa A; Stommel JM; Stegh A; Hahn WC; Ligon KL; Louis DN; Brennan C; Chin L; DePinho RA; Cavenee WK
Genes Dev; 2007 Nov; 21(21):2683-710. PubMed ID: 17974913
[TBL] [Abstract][Full Text] [Related]
19. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor.
Zhang X; Gureasko J; Shen K; Cole PA; Kuriyan J
Cell; 2006 Jun; 125(6):1137-49. PubMed ID: 16777603
[TBL] [Abstract][Full Text] [Related]
20. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.
Mellinghoff IK; Wang MY; Vivanco I; Haas-Kogan DA; Zhu S; Dia EQ; Lu KV; Yoshimoto K; Huang JH; Chute DJ; Riggs BL; Horvath S; Liau LM; Cavenee WK; Rao PN; Beroukhim R; Peck TC; Lee JC; Sellers WR; Stokoe D; Prados M; Cloughesy TF; Sawyers CL; Mischel PS
N Engl J Med; 2005 Nov; 353(19):2012-24. PubMed ID: 16282176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
